Editing Castrate-Resistant Prostate Cancer

Revision as of 08:43, 17 December 2021 by Urology4all (talk | contribs) (Created page with "'''See 2021 CUA CRPC Guideline Notes''' '''See 2020 AUA Advanced Prostate Cancer Guideline Notes''' '''Includes 2021 CUA CRPC Guidelines''' == Background == * '''Treatment with androgen-deprivation therapy (ADT) almost always leads to resistance to ADT''' (i.e., cancer progression despite castrate levels of serum testosterone i.e. castrate-resistent prostate cancer) ** '''Follow-up in patients treated with ADT''' **# '''PSA''' **# '''Imaging (bone scan and CT scan)''...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Warning: You are editing an out-of-date revision of this page. If you publish it, any changes made since this revision will be lost.
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see UrologySchool.com:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)